The distinctive expression of ROR1 and its putative role in cancer progression has stimulated development and testing of agents that can target surface ROR1 for the treatment of patients with cancer, such as anti-ROR1 mAbs, antibody–drug conjugates (ADC), bispecific antibodies, and CAR T cells, as well as small-molecule inhibitors (reviewed in [8]). Here, ROR1 is linked to cancer.